Ovid Starts Neurology Spree With AstraZeneca Deal

The company is using proceeds from last year’s handover of its lead epilepsy program to Takeda to fuel a push in neurology development.

Epilepsy brain
Ovid announced an in-licensing deal with AstraZeneca for a library of KCC2 transporter-targeting drugs • Source: Shutterstock

Ovid Therapeutics, Inc. is kicking off the new year with a multimillion-dollar licensing deal with AstraZeneca PLC that Ovid CEO Jeremy Levin said is one component of a broader development strategy in neurology, which it is financing with the help of an out-licensing agreement in early 2021 with Takeda Pharmaceutical Co. Ltd.

The company said on 3 January that it had licensed from AstraZeneca a library of early-stage small molecule drugs that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category